22 research outputs found

    Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives

    No full text
    Deregulation of c-Met receptor tyrosine kinase activity leads to tumorigenesis and metastasis in animal models. More importantly, the identification of activating mutations in c-Met, as well as <i>MET</i> gene amplification in human cancers, points to c-Met as an important target for cancer therapy. We have previously described two classes of c-Met kinase inhibitors (class I and class II) that differ in their binding modes and selectivity profiles. The class II inhibitors tend to have activities on multiple kinases. Knowledge of the binding mode of these molecules in the c-Met protein led to the design and evaluation of several new class II c-Met inhibitors that utilize various 5-membered cyclic carboxamides to conformationally restrain key pharmacophoric groups within the molecule. These investigations resulted in the identification of a potent and novel class of pyrazolone c-Met inhibitors with good in vivo activity

    Robust direct effect of carbon dioxide on tropical circulation and regional precipitation

    No full text
    International audiencePredicting the response of tropical rainfall to climate change remains a challenge(1). Rising concentrations of carbon dioxide are expected to affect the hydrological cycle through increases in global mean temperature and the water vapour content of the atmosphere(2-4). However, regional precipitation changes also closely depend on the atmospheric circulation, which is expected to weaken in a warmer world(4-6). Here, we assess the effect of a rise in atmospheric carbon dioxide concentrations on tropical circulation and precipitation by analysing results from a suite of simulations from multiple state-of-the-art climate models, and an operational numerical weather prediction model. In a scenario in which humans continue to use fossil fuels unabated, about half the tropical circulation change projected by the end of the twenty-first century, and consequently a large fraction of the regional precipitation change, is independent of global surfacewarming. Instead, these robust circulation and precipitation changes are a consequence of the weaker net radiative cooling of the atmosphere associated with higher atmospheric carbon dioxide levels, which affects the strength of atmospheric vertical motions. This implies that geo-engineering schemes aimed at reducing global warming without removing carbon dioxide from the atmosphere would fail to fully mitigate precipitation changes in the tropics. Strategies that may help constrain rainfall projections are suggested

    Structure-Based Design of Novel Class II c-Met Inhibitors: 2. SAR and Kinase Selectivity Profiles of the Pyrazolone Series

    No full text
    As part of our effort toward developing an effective therapeutic agent for c-Met-dependent tumors, a pyrazolone-based class II c-Met inhibitor, <i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)­oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1<i>H</i>-pyrazole-4-carboxamide (<b>1</b>), was identified. Knowledge of the binding mode of this molecule in both c-Met and VEGFR-2 proteins led to a novel strategy for designing more selective analogues of <b>1</b>. Along with detailed SAR information, we demonstrate that the low kinase selectivity associated with class II c-Met inhibitors can be improved significantly. This work resulted in the discovery of potent c-Met inhibitors with improved selectivity profiles over VEGFR-2 and IGF-1R that could serve as useful tools to probe the relationship between kinase selectivity and in vivo efficacy in tumor xenograft models. Compound <b>59e</b> (AMG 458) was ultimately advanced into preclinical safety studies

    Identification of (<i>R</i>)‑<i>N</i>‑((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)‑1<i>H</i>‑indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B‑Cell Lymphomas

    No full text
    Polycomb repressive complex 2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3. Dysregulation of PRC2 function correlates with certain malignancies and poor prognosis. EZH2 is the catalytic engine of the PRC2 complex and thus represents a key candidate oncology target for pharmacological intervention. Here we report the optimization of our indole-based EZH2 inhibitor series that led to the identification of CPI-1205, a highly potent (biochemical IC<sub>50</sub> = 0.002 ÎŒM, cellular EC<sub>50</sub> = 0.032 ÎŒM) and selective inhibitor of EZH2. This compound demonstrates robust antitumor effects in a Karpas-422 xenograft model when dosed at 160 mg/kg BID and is currently in Phase I clinical trials. Additionally, we disclose the co-crystal structure of our inhibitor series bound to the human PRC2 complex
    corecore